Drug intelligence / Profile preview

BRII-732

Development stage: Unknown
Lead developer: Brii Biosciences
Modality: Small Molecules
Administration: Oral

Overview

BRII-732 is a medoxomil carbonate prodrug of islatravir (ISL/EFdA), a potent HIV-1 nucleotide reverse transcriptase translocation inhibitor. It is designed for once-weekly dosing as part of combination antiretroviral therapy for HIV. Following oral absorption, BRII-732 is efficiently converted to islatravir in vivo with no measurable systemic exposure to the prodrug itself. It demonstrates a long half-life, dose-dependent pharmacokinetic profile, and efficient intracellular formation of ISL-TP in peripheral blood mononuclear cells (PBMCs).

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on BRII-732.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRII-732.

Explore the full profile